1801185-08-9

Name	Methanone, [(3S)-3-[[4-(1,1-dimethylethoxy)phenoxy]methyl]-6-fluoro-3,4-dihydro-2(1H)-isoquinolinyl]-1-naphthalenyl-
CAS	1801185-08-9
Molecular Formula	C31H30FNO3
Molecular Weight	483.57
MOL File	1801185-08-9.mol

Synonyms

SR12418 Methanone, [(3S)-3-[[4-(1,1-dimethylethoxy)phenoxy]methyl]-6-fluoro-3,4-dihydro-2(1H)-isoquinolinyl]-1-naphthalenyl-

show less show more

Chemical Properties

Boiling point	645.1±55.0 °C(Predicted)
density	1.191±0.06 g/cm3(Predicted)
form	Solid
pka	-2.21±0.40(Predicted)
color	White to off-white

Hazard Information

Uses

SR12418 is a REV-ERB-specific synthetic ligand with IC50s of 68 nM and 119 nM for REV-ERBα and REV-ERBβ, respectively. SR12418 can be used in experimental autoimmune encephalomyelitis (EAE) and colitis research[1][2].

in vivo

SR12418 (intraperitoneal injection; 50 mg/kg; twice a day) suppresses the development and severity of experimental autoimmune encephalomyelitis^[1]. SR12418 (intraperitoneal injection; 50 mg/kg; twice a day; begin at day 18 post-immunization) shows effects in intervention studies of relapsing-remitting experimental autoimmune encephalomyelitis^[1].

Animal Model:	C57BL/6 mice inducing experimental autoimmune encephalomyelitis (EAE)^[1]
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; 50 mg/kg; twice a day
Result:	Diminished the incidence of disease with approximately 20% mice developing disease. Showed no overt signs of toxicity.

Animal Model:	PLP139-151-induced relapsing-remitting EAE (R-EAE) in SJL/J mice^[1]
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; 50 mg/kg; twice a day; begin at day 18 post-immunization
Result:	Resulted in a significant reduction in the relapse severity compared to the vehicle control. Showed a significant decrease in the frequency and number of CD4⁺ and CD8⁺ effector cells (CD44^hi).

References

[1] Mohammed Amir, et al. REV-ERBα Regulates TH17 Cell Development and Autoimmunity. Cell Rep. 2018 Dec 26;25(13):3733-3749.e8. DOI:10.1016/j.celrep.2018.11.101
[2] Shuai Wang, et al. Targeting REV-ERBα for therapeutic purposes: promises and challenges. Theranostics. 2020 Mar 4;10(9):4168-4182. DOI:10.7150/thno.43834

Supplier

Tianjin Kailiqi Biotechnology Co., Ltd.

Telephone 15076683720

Websitehttp://www.cw-bio.com

Suzhou youruike Chemical Pharmaceutical Technology Co., Ltd

Telephone 15317229551

Websitehttps://www.ureiko.com

Bide Pharmatech Ltd.

Telephone400-1647117 13681763483

Websitehttps://www.bidepharm.com/

Shanghai Yifei Biotechnology Co. , Ltd.

Telephone021-65675885 18964387627

Websitehttp://www.efebio.com

TargetMol Chemicals Inc.

Telephone 15002134094

Websitehttps://www.targetmol.cn/

PROMPT×

PROMPT
The What'sApp is temporarily not supported in mainland China

Cancel

Determine

Send Inquriy